{"id":32968,"date":"2013-05-23T10:23:05","date_gmt":"2013-05-23T14:23:05","guid":{"rendered":"http:\/\/asweetlife.org\/?post_type=news&#038;p=32968"},"modified":"2015-12-30T05:10:39","modified_gmt":"2015-12-30T10:10:39","slug":"elderly-type-2-diabetes-patients-achieve-target-hba1c-with-novartis-galvus-vildagliptin","status":"publish","type":"post","link":"https:\/\/asweetlife.org\/?p=32968","title":{"rendered":"Elderly Type 2 Diabetes Patients Achieve Target HbA1c with Novartis&#8217; Galvus (vildagliptin)"},"content":{"rendered":"<p style=\"text-align: justify;\"><a href=\"https:\/\/asweetlife.org\/wp-content\/uploads\/2013\/05\/Novartislogo-1.png\" rel=\"mfp\"><img decoding=\"async\" class=\"alignleft size-full wp-image-32969 lazyload\" title=\"Novartislogo\" src=\"data:image\/gif;base64,R0lGODlhAQABAAAAACH5BAEKAAEALAAAAAABAAEAAAICTAEAOw==\" data-src=\"https:\/\/asweetlife.org\/wp-content\/uploads\/2013\/05\/Novartislogo-1.png\" alt=\"\" width=\"200\" height=\"130\" \/><\/a>Results of the\u00a0Novartis-sponsored\u00a0INTERVAL study\u00a0have\u00a0demonstrated the feasibility of setting and achieving individualized treatment targets in elderly patients with type 2 diabetes treated with Novartis drug,\u00a0Galvus\u00a0(vildagliptin). \u00a0In previous large-scale studies, which used aggressive, identical HbA1c targets for all patients with type 2 diabetes, elderly patients failed to reach treatment goals.\u00a0<\/p>\n<div style=\"text-align: justify;\">Current treatment guidelines recommend individualized goals in elderly patients based on characteristics such as age, comorbidities and frailty; however, no studies using individual targets have previously been conducted.<\/div>\n<div style=\"text-align: justify;\">\u00a0<\/div>\n<div style=\"text-align: justify;\">The INTERVAL study introduced the unique endpoint of investigator-defined individualized HbA1c targets, reflecting guidance in current guidelines. In the study, elderly patients with type 2 diabetes who were treated with Galvus\u00a0(vildagliptin) achieved greater reductions in HbA1c and were three times more likely to reach individualized treatment goals without major tolerability issues than those treated with placebo on top of background oral antidiabetic treatment.<\/div>\n<div style=\"text-align: justify;\">\u00a0<\/div>\n<div style=\"text-align: justify;\">In the 24-week INTERVAL study, 52.6 percent of patients treated with vildagliptin achieved unique, investigator-identified individualized treatment goals compared to 27 percent of patients treated with placebo (adjusted odds ratio 3.16, 96.2% CI 1.81 to 5.52; p&lt;0.0001). Patients treated with vildagliptin also achieved clinically relevant reductions in HbA1c of 0.9% from a baseline compared to a 0.3% reduction from a baseline in those treated with placebo, a difference of 0.6% (98.8% CI -0.81 to -0.33; p&lt;0.0001)[1]. \u00a0Average baseline HbA1c values for both groups were 7.9%. The overall safety and tolerability profile was similar in the vildagliptin and placebo groups, with a low incidence of hypoglycemia, no reported cases of pancreatitis or clinically significant hepatic-related events, and no new safety signals.<\/div>\n<div style=\"text-align: justify;\">\u00a0<\/div>\n<div style=\"text-align: justify;\">Results from the\u00a0INTERVAL study were published in the Lancet<\/div>\n","protected":false},"excerpt":{"rendered":"<p>Results of the Novartis-sponsored INTERVAL study have demonstrated the feasibility of setting and achieving individualized treatment targets in elderly patients with type 2 diabetes treated with Novartis drug, Galvus (vildagliptin).<\/p>\n","protected":false},"author":131,"featured_media":32969,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_relevanssi_hide_post":"","_relevanssi_hide_content":"","_relevanssi_pin_for_all":"","_relevanssi_pin_keywords":"","_relevanssi_unpin_keywords":"","_relevanssi_related_keywords":"","_relevanssi_related_include_ids":"","_relevanssi_related_exclude_ids":"","_relevanssi_related_no_append":"","_relevanssi_related_not_related":"","_relevanssi_related_posts":"","_relevanssi_noindex_reason":"","footnotes":""},"categories":[1442],"tags":[1296],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v22.9 (Yoast SEO v22.9) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Elderly Type 2 Diabetes Patients Achieve Target HbA1c with Novartis&#039; Galvus (vildagliptin)<\/title>\n<meta name=\"description\" content=\"Results of the Novartis-sponsored INTERVAL study have demonstrated the feasibility of setting and achieving individualized treatment targets in elderly patients with type 2 diabetes treated with Novartis drug, Galvus (vildagliptin).\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/asweetlife.org\/?p=32968\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"ASweetLife Team\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/asweetlife.org\/?p=32968\",\"url\":\"https:\/\/asweetlife.org\/?p=32968\",\"name\":\"Elderly Type 2 Diabetes Patients Achieve Target HbA1c with Novartis' Galvus (vildagliptin)\",\"isPartOf\":{\"@id\":\"https:\/\/asweetlife.org\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/asweetlife.org\/?p=32968#primaryimage\"},\"image\":{\"@id\":\"https:\/\/asweetlife.org\/?p=32968#primaryimage\"},\"thumbnailUrl\":\"https:\/\/asweetlife.org\/wp-content\/uploads\/2013\/05\/Novartislogo-1.png\",\"datePublished\":\"2013-05-23T14:23:05+00:00\",\"dateModified\":\"2015-12-30T10:10:39+00:00\",\"author\":{\"@id\":\"https:\/\/asweetlife.org\/#\/schema\/person\/5de2b093878b82b0ea97917f8fd72585\"},\"description\":\"Results of the Novartis-sponsored INTERVAL study have demonstrated the feasibility of setting and achieving individualized treatment targets in elderly patients with type 2 diabetes treated with Novartis drug, Galvus (vildagliptin).\",\"breadcrumb\":{\"@id\":\"https:\/\/asweetlife.org\/?p=32968#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/asweetlife.org\/?p=32968\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/asweetlife.org\/?p=32968#primaryimage\",\"url\":\"https:\/\/asweetlife.org\/wp-content\/uploads\/2013\/05\/Novartislogo-1.png\",\"contentUrl\":\"https:\/\/asweetlife.org\/wp-content\/uploads\/2013\/05\/Novartislogo-1.png\",\"width\":200,\"height\":130,\"caption\":\"Novartislogo\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/asweetlife.org\/?p=32968#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/asweetlife.org\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Elderly Type 2 Diabetes Patients Achieve Target HbA1c with Novartis&#8217; Galvus (vildagliptin)\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/asweetlife.org\/#website\",\"url\":\"https:\/\/asweetlife.org\/\",\"name\":\"ASweetLife\",\"description\":\"The Diabetes Magazine\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/asweetlife.org\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/asweetlife.org\/#\/schema\/person\/5de2b093878b82b0ea97917f8fd72585\",\"name\":\"ASweetLife Team\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/asweetlife.org\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/ba76b5c6c27d32738b13f9a8a5cfcf02?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/ba76b5c6c27d32738b13f9a8a5cfcf02?s=96&d=mm&r=g\",\"caption\":\"ASweetLife Team\"},\"url\":\"https:\/\/asweetlife.org\/?author=131\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Elderly Type 2 Diabetes Patients Achieve Target HbA1c with Novartis' Galvus (vildagliptin)","description":"Results of the Novartis-sponsored INTERVAL study have demonstrated the feasibility of setting and achieving individualized treatment targets in elderly patients with type 2 diabetes treated with Novartis drug, Galvus (vildagliptin).","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/asweetlife.org\/?p=32968","twitter_misc":{"Written by":"ASweetLife Team","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/asweetlife.org\/?p=32968","url":"https:\/\/asweetlife.org\/?p=32968","name":"Elderly Type 2 Diabetes Patients Achieve Target HbA1c with Novartis' Galvus (vildagliptin)","isPartOf":{"@id":"https:\/\/asweetlife.org\/#website"},"primaryImageOfPage":{"@id":"https:\/\/asweetlife.org\/?p=32968#primaryimage"},"image":{"@id":"https:\/\/asweetlife.org\/?p=32968#primaryimage"},"thumbnailUrl":"https:\/\/asweetlife.org\/wp-content\/uploads\/2013\/05\/Novartislogo-1.png","datePublished":"2013-05-23T14:23:05+00:00","dateModified":"2015-12-30T10:10:39+00:00","author":{"@id":"https:\/\/asweetlife.org\/#\/schema\/person\/5de2b093878b82b0ea97917f8fd72585"},"description":"Results of the Novartis-sponsored INTERVAL study have demonstrated the feasibility of setting and achieving individualized treatment targets in elderly patients with type 2 diabetes treated with Novartis drug, Galvus (vildagliptin).","breadcrumb":{"@id":"https:\/\/asweetlife.org\/?p=32968#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/asweetlife.org\/?p=32968"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/asweetlife.org\/?p=32968#primaryimage","url":"https:\/\/asweetlife.org\/wp-content\/uploads\/2013\/05\/Novartislogo-1.png","contentUrl":"https:\/\/asweetlife.org\/wp-content\/uploads\/2013\/05\/Novartislogo-1.png","width":200,"height":130,"caption":"Novartislogo"},{"@type":"BreadcrumbList","@id":"https:\/\/asweetlife.org\/?p=32968#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/asweetlife.org\/"},{"@type":"ListItem","position":2,"name":"Elderly Type 2 Diabetes Patients Achieve Target HbA1c with Novartis&#8217; Galvus (vildagliptin)"}]},{"@type":"WebSite","@id":"https:\/\/asweetlife.org\/#website","url":"https:\/\/asweetlife.org\/","name":"ASweetLife","description":"The Diabetes Magazine","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/asweetlife.org\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/asweetlife.org\/#\/schema\/person\/5de2b093878b82b0ea97917f8fd72585","name":"ASweetLife Team","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/asweetlife.org\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/ba76b5c6c27d32738b13f9a8a5cfcf02?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/ba76b5c6c27d32738b13f9a8a5cfcf02?s=96&d=mm&r=g","caption":"ASweetLife Team"},"url":"https:\/\/asweetlife.org\/?author=131"}]}},"_links":{"self":[{"href":"https:\/\/asweetlife.org\/index.php?rest_route=\/wp\/v2\/posts\/32968"}],"collection":[{"href":"https:\/\/asweetlife.org\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/asweetlife.org\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/asweetlife.org\/index.php?rest_route=\/wp\/v2\/users\/131"}],"replies":[{"embeddable":true,"href":"https:\/\/asweetlife.org\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=32968"}],"version-history":[{"count":0,"href":"https:\/\/asweetlife.org\/index.php?rest_route=\/wp\/v2\/posts\/32968\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/asweetlife.org\/index.php?rest_route=\/wp\/v2\/media\/32969"}],"wp:attachment":[{"href":"https:\/\/asweetlife.org\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=32968"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/asweetlife.org\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=32968"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/asweetlife.org\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=32968"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}